Driving innovation in India’s diagnostic industry

India is embracing a transformative wave guided by Make in India and Develop in India principles. With the medical devices market expected to surpass USD 20 billion by 2027, and grow at an annual rate of 17 percent, Erba Transasia Group – India’s leading homegrown in-vitro diagnostic company – is at the forefront of this monumental shift. Every year, over 150 crore tests are conducted on Erba analyzers, a staggering number equivalent to the entire population of the country.

Our vision is deeply rooted in addressing the challenges posed by the uneven distribution of healthcare infrastructure across our vast nation. Our strategy revolves around reducing dependency on imports and fostering self-reliance.

Our approach is built on five core pillars – advancing our product portfolio through cutting-edge research and development; scaling our manufacturing capabilities to meet global standards; ensuring widespread access to diagnostic services; ongoing educational programs; and addressing the skilling gap.

Enhancing product portfolio
Erba’s state-of-the-art R&D facilities in Mumbai and Bangalore, India, as well as in France and Austria, have collaborated to unveil an array of groundbreaking products in 2024:

• Immunoassay range – Apex and Vertex. Utilizing Chemiluminescence technology, our soon-to-be launched immunoassay range offers reliable and accessible solutions for labs, with over 40 parameters to streamline workflow, optimize space usage, and accelerate turnaround times.
• Real-time PCR system – MX8. This four-channel, fully automated molecular analyzer offers a sample-to-result time of under 120 minutes for 8 samples. It is designed for decentralized testing, featuring closed extraction and amplification to increase specificity and mitigate contamination risks.
• Advanced hematology analyzer – H7100. This advanced analyzer with Retics provides an extensive parameter range, crucial for diagnosing and monitoring anemia, thrombocytopenia, thrombocytosis, infection, inflammation, and myeloid neoplasms.
• Sickle cell rapid test kits. Developed to support India’s mission to eliminate sickle cell anemia by 2047, these homegrown kits use competitive lateral flow technology to deliver 100-percent sensitivity and specificity as validated by ICMR.
• Erba LIMS software. Our new LIMS software with a mobile app provides high-function device interfacing and remote online approval of patient reports, eliminating the need for expensive LIS systems, especially for independent labs.

Scaling local manufacturing
We commend the Indian government’s initiative in establishing dedicated MedTech parks, which are instrumental in promoting indigenous production. Our forthcoming factory of the future in Vizag AMTZ will be spread over 50,000 sq. ft. This will complement our existing five factories in India and one in the Czech Republic.

At Erba Transasia, we are dedicated not only to manufacturing but also to education and research. We are proud to lead the establishment of India’s first MedTech University, Erba Global University, which will offer advanced, research-based education in medical technology, preparing the next generation of professionals to drive innovation in this field.

Driving accessibility
Through our extensive distribution network of over 500 distributors, complemented by our dedicated field staff of 900, and by training local healthcare professionals, we ensure that our products reach the remotest towns and villages with limited access to advanced medical technology. We are the preferred partner for small independent labs seeking cost-effective, reliable solutions. Our collaboration with non-governmental organizations supports outreach programs that educate and empower communities on preventive healthcare. After reaching out and engaging with more than 100 pathologists and laboratory owners, I am convinced that exceptional customer service is our raison d’etre, and we must absolutely preserve and enhance it.

Educational symposia
Our ongoing educational programs are aimed at informing the IVD fraternity about the latest technological advancements. We provide valuable clinical data and scientific updates periodically to further advocate our technologies. Our scientific advisory board, composed of key opinion leaders, plays a crucial role in identifying and addressing current and future needs. Their expertise guides the implementation of our plans for future growth.

Community outreach programs
We will continue to support communities through our corporate social responsibility initiatives. For instance, the Erba Institute of Laboratory Technology has been established to address the critical shortage of qualified and well-trained lab technicians. We are committed to expanding this facility to reach and benefit a larger number of individuals.

We are dedicated to leading innovation and creating a healthier and happier world, together with our partners.